Skip to main content
Figure 4 | Cardiovascular Diabetology

Figure 4

From: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Figure 4

Effects of short-term (7 days) empagliflozin administration on non-fasting blood glucose (A), 24 hr-urinary glucose excretion (B), 24 hr-urine volume (C), 24 hr-urinary sodium excretion (D), body weight gain (E), food intake (F), water intake (G), and serum insulin level (H) of db/m mice. Abbreviations: db/m, non-diabetic db/m mice; Control, control (untreated) db/m mice; Empa, empagliflozin-treated db/m mice. *p < 0.05, †p < 0.01, vs control db/m mice. Values are mean ± SEM (n = 10).

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840